{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Makhlin I"],"funding":["Susan G. Komen","National Cancer Institute","NCI NIH HHS"],"pagination":["e220032"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9713595"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["4(6)"],"pubmed_abstract":["Fluorine 18 (<sup>18</sup>F) fluorodeoxyglucose (FDG) PET/CT has shown promise for use in assessing treatment response in patients with bone-only or bone-dominant (BD) metastatic breast cancer (mBC). In this single-institution, prospective single-arm study of 23 women (median age, 59 years [range, 38-81 years]) with biopsy-proven estrogen receptor-positive bone-only or BD mBC about to begin new endocrine therapy between October 3, 2013, and August 3, 2018, the value of early 4-week <sup>18</sup>F-FDG PET/CT in predicting progression-free survival (PFS) was evaluated. <sup>18</sup>F-FDG PET/CT was performed at baseline, 4 weeks, and 12 weeks. Maximum standardized uptake value (SUV<sub>max</sub>) and peak SUV (SUV<sub>peak</sub>) were measured for up to five index lesions. The primary end point was PFS. Secondary end points were overall survival (OS) and time to skeletal-related events (tSREs). All end points were compared between responders (reduction of 30% or more in the sum of SUV<sub>max</sub> for target lesions) and nonresponders at 4 weeks and 12 weeks. Percentage change from baseline in SUV<sub>max</sub> at 4- and 12-week <sup>18</sup>F-FDG PET/CT were highly correlated (<i>r</i> = 0.81). At the 4-week time point PET responders had numerically longer PFS (14.2 months vs 6.3 months; <i>P</i> = .53), OS (44.0 months vs 29.7 months; <i>P</i> = .47), and tSRE (27.4 months vs 25.2 months; <i>P</i> = .66) compared with nonresponders, suggesting the clinical utility of 4-week <sup>18</sup>F-FDG PET/CT as an early predictor of treatment failure. <b>Keywords:</b> Breast Cancer, Metastatic Breast Cancer, Bone-Dominant Metastatic Breast Cancer, FDG PET/CT, Estrogen-Receptor Positive Metastatic Breast Cancer <i>Supplemental material is available for this article.</i> Clinical trial registration no. NCT04316117 © RSNA, 2022."],"journal":["Radiology. Imaging cancer"],"pubmed_title":["<sup>18</sup>F-FDG PET/CT for the Evaluation of Therapy Response in Hormone Receptor-Positive Bone-Dominant Metastatic Breast Cancer."],"pmcid":["PMC9713595"],"funding_grant_id":["T32 CA009615-30","T32 CA009615"],"pubmed_authors":["Gillman J","Makhlin I","Pantel AR","Mankoff DA","Clark AS","Korhonen KE","Martin ML","Schubert E"],"additional_accession":[]},"is_claimable":false,"name":"<sup>18</sup>F-FDG PET/CT for the Evaluation of Therapy Response in Hormone Receptor-Positive Bone-Dominant Metastatic Breast Cancer.","description":"Fluorine 18 (<sup>18</sup>F) fluorodeoxyglucose (FDG) PET/CT has shown promise for use in assessing treatment response in patients with bone-only or bone-dominant (BD) metastatic breast cancer (mBC). In this single-institution, prospective single-arm study of 23 women (median age, 59 years [range, 38-81 years]) with biopsy-proven estrogen receptor-positive bone-only or BD mBC about to begin new endocrine therapy between October 3, 2013, and August 3, 2018, the value of early 4-week <sup>18</sup>F-FDG PET/CT in predicting progression-free survival (PFS) was evaluated. <sup>18</sup>F-FDG PET/CT was performed at baseline, 4 weeks, and 12 weeks. Maximum standardized uptake value (SUV<sub>max</sub>) and peak SUV (SUV<sub>peak</sub>) were measured for up to five index lesions. The primary end point was PFS. Secondary end points were overall survival (OS) and time to skeletal-related events (tSREs). All end points were compared between responders (reduction of 30% or more in the sum of SUV<sub>max</sub> for target lesions) and nonresponders at 4 weeks and 12 weeks. Percentage change from baseline in SUV<sub>max</sub> at 4- and 12-week <sup>18</sup>F-FDG PET/CT were highly correlated (<i>r</i> = 0.81). At the 4-week time point PET responders had numerically longer PFS (14.2 months vs 6.3 months; <i>P</i> = .53), OS (44.0 months vs 29.7 months; <i>P</i> = .47), and tSRE (27.4 months vs 25.2 months; <i>P</i> = .66) compared with nonresponders, suggesting the clinical utility of 4-week <sup>18</sup>F-FDG PET/CT as an early predictor of treatment failure. <b>Keywords:</b> Breast Cancer, Metastatic Breast Cancer, Bone-Dominant Metastatic Breast Cancer, FDG PET/CT, Estrogen-Receptor Positive Metastatic Breast Cancer <i>Supplemental material is available for this article.</i> Clinical trial registration no. NCT04316117 © RSNA, 2022.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-04-04T21:00:41.501Z","creation":"2025-04-04T21:00:41.501Z"},"accession":"S-EPMC9713595","cross_references":{"pubmed":["36269154"],"doi":["10.1148/rycan.220032"]}}